MYC and cancer: Indeed, multiple mouse models have demonstrated that even transient inactivation of MYC elicits tumor regression, suggesting that regulation of oncogenic MYC could be harnessed to treat cancer patients.17,18,99 However, MYC lacks a specific active site for small molecules, making it difficult to functionally inhibit its activities using strategies similar to those used for kinases.